Literature DB >> 29323345

Osteoporosis in 2017: Addressing the crisis in the treatment of osteoporosis.

Christian Roux1, Karine Briot1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29323345     DOI： 10.1038/nrrheum.2017.218

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  A Crisis in the Treatment of Osteoporosis.

Authors:  Sundeep Khosla; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2016-06-28       Impact factor: 6.741

2.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David L Kendler; Fernando Marin; Cristiano A F Zerbini; Luis A Russo; Susan L Greenspan; Vit Zikan; Alicia Bagur; Jorge Malouf-Sierra; Péter Lakatos; Astrid Fahrleitner-Pammer; Eric Lespessailles; Salvatore Minisola; Jean Jacques Body; Piet Geusens; Rüdiger Möricke; Pedro López-Romero
Journal:  Lancet       Date:  2017-11-09       Impact factor: 79.321

3.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Authors:  Felicia Cosman; Daria B Crittenden; Jonathan D Adachi; Neil Binkley; Edward Czerwinski; Serge Ferrari; Lorenz C Hofbauer; Edith Lau; E Michael Lewiecki; Akimitsu Miyauchi; Cristiano A F Zerbini; Cassandra E Milmont; Li Chen; Judy Maddox; Paul D Meisner; Cesar Libanati; Andreas Grauer
Journal:  N Engl J Med       Date:  2016-09-18       Impact factor: 91.245

4.  Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Authors:  Paul D Miller; Gary Hattersley; Bente Juel Riis; Gregory C Williams; Edith Lau; Luis Augusto Russo; Peter Alexandersen; Cristiano A F Zerbini; Ming-yi Hu; Alan G Harris; Lorraine A Fitzpatrick; Felicia Cosman; Claus Christiansen
Journal:  JAMA       Date:  2016-08-16       Impact factor: 56.272

5.  Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.

Authors:  Felicia Cosman; Paul D Miller; Gregory C Williams; Gary Hattersley; Ming-Yi Hu; Ivo Valter; Lorraine A Fitzpatrick; Bente Juel Riis; Claus Christiansen; John P Bilezikian; Dennis Black
Journal:  Mayo Clin Proc       Date:  2017-02       Impact factor: 7.616

6.  10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Authors:  Henry G Bone; Rachel B Wagman; Maria L Brandi; Jacques P Brown; Roland Chapurlat; Steven R Cummings; Edward Czerwiński; Astrid Fahrleitner-Pammer; David L Kendler; Kurt Lippuner; Jean-Yves Reginster; Christian Roux; Jorge Malouf; Michelle N Bradley; Nadia S Daizadeh; Andrea Wang; Paula Dakin; Nicola Pannacciulli; David W Dempster; Socrates Papapoulos
Journal:  Lancet Diabetes Endocrinol       Date:  2017-05-22       Impact factor: 32.069

7.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Authors:  Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

8.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

9.  Barriers to Effective Postmenopausal Osteoporosis Treatment: A Qualitative Study of Patients' and Practitioners' Views.

Authors:  Sophie Alami; Lucile Hervouet; Serge Poiraudeau; Karine Briot; Christian Roux
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

10.  Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry.

Authors:  Rama Kalluru; Keith J Petrie; Andrew Grey; Zaynah Nisa; Anne M Horne; Greg D Gamble; Mark J Bolland
Journal:  BMJ Open       Date:  2017-02-10       Impact factor: 2.692
  10 in total
  5 in total

1.  The clinician's guide to prevention and treatment of osteoporosis.

Authors:  M S LeBoff; S L Greenspan; K L Insogna; E M Lewiecki; K G Saag; A J Singer; E S Siris
Journal:  Osteoporos Int       Date:  2022-04-28       Impact factor: 5.071

2.  Up-regulated CST5 inhibits bone resorption and activation of osteoclasts in rat models of osteoporosis via suppression of the NF-κB pathway.

Authors:  Fei Wang; Chuanzhu Zhang; Wei Ge; Guoqiang Zhang
Journal:  J Cell Mol Med       Date:  2019-08-11       Impact factor: 5.310

Review 3.  Body composition adaptations to lower-body plyometric training: a systematic review and meta-analysis.

Authors:  Rodrigo Ramirez-Campillo; Felipe García-Pinillos; Pantelis T Nikolaidis; Filipe Manuel Clemente; Paulo Gentil; Antonio García-Hermoso
Journal:  Biol Sport       Date:  2021-04-09       Impact factor: 2.806

4.  Serum exosomes from young rats improve the reduced osteogenic differentiation of BMSCs in aged rats with osteoporosis after fatigue loading in vivo.

Authors:  Jingqiong Xun; Chan Li; Meilu Liu; Yueming Mei; Qiongfei Zhou; Bo Wu; Fen Xie; Yuling Liu; Ruchun Dai
Journal:  Stem Cell Res Ther       Date:  2021-07-27       Impact factor: 6.832

5.  GAS5 protects against osteoporosis by targeting UPF1/SMAD7 axis in osteoblast differentiation.

Authors:  Ming Li; Zhongyu Xie; Jinteng Li; Jiajie Lin; Guan Zheng; Wenjie Liu; Su'an Tang; Shuizhong Cen; Guiwen Ye; Zhaofeng Li; Wenhui Yu; Peng Wang; Yanfeng Wu; Huiyong Shen
Journal:  Elife       Date:  2020-10-02       Impact factor: 8.140
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.